

Johannes Levin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/44294/publications.pdf>

Version: 2024-02-01

223
papers

12,548
citations

36299

51
h-index

32838

100
g-index

271
all docs

271
docs citations

271
times ranked

14436
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284.	0.8	2
2	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	1.2	18
3	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168.	1.9	7
4	Seizure prevalence in neurodegenerative diseases—a study of autopsy proven cases. <i>European Journal of Neurology</i> , 2022, 29, 12-18.	3.3	6
5	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	7.6	27
6	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH : A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	5.3	21
7	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1754-1764.	0.8	4
8	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
9	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14.	2.6	3
10	Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. <i>EMBO Journal</i> , 2022, 41, e109108.	7.8	38
11	Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 261.	9.0	15
12	Impact of Partial Volume Correction on ^{18}F GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome. <i>Brain Sciences</i> , 2022, 12, 204.	2.3	2
13	Variant-dependent heterogeneity in amyloid $\text{A}\beta$ burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , The, 2022, 21, 140-152.	10.2	34
14	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	2.4	2
15	Data-driven staging of genetic frontotemporal dementia using multi-modal MRI . <i>Human Brain Mapping</i> , 2022, 43, 1821-1835.	3.6	7
16	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.8	24
17	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
18	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 2687-2698.	0.8	13

#	ARTICLE	IF	CITATIONS
19	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	3.6	1
20	The ^{CBI&R} detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
21	Serum ^{Beta&Synuclein} Is Higher in Down Syndrome and Precedes Rise of ^{pTau181}. Annals of Neurology, 2022, 92, 6-10.	5.3	9
22	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
23	COVID-19 Vaccination of Individuals with Down Syndrome&Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. Vaccines, 2022, 10, 530.	4.4	8
24	Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer&TM's Disease. Biomolecules, 2022, 12, 458.	4.0	9
25	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	10.2	72
26	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	4.4	7
27	¹⁸F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy. Journal of Nuclear Medicine, 2022, , jnumed.121.262854.	5.0	8
28	Effects of Low-Intensity Vestibular Noise Stimulation on Postural Instability in Patients with Parkinson&TM's Disease. Journal of Parkinson's Disease, 2022, 12, 1611-1618.	2.8	3
29	Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine, 2022, 80, 104021.	6.1	26
30	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.1	5
31	Autosomal dominant and sporadic late onset Alzheimer's disease share a common<i>in vivo</i>pathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
32	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	2.5	9
33	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer&TM's Disease. Biological Psychiatry, 2021, 89, 776-785.	1.3	30
34	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer&TM's disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
35	Biphasic cortical macro&and microstructural changes in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 618-628.	0.8	27
36	In Vivo Assessment of Neuroinflammation in ^{4&Repeat} Tauopathies. Movement Disorders, 2021, 36, 883-894.	3.9	37

#	ARTICLE	IF	CITATIONS
37	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.8	36
38	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.8	31
39	Inter-hospital transfer for mechanical thrombectomy within the supraregional stroke network NEVAS. <i>Journal of Neurology</i> , 2021, 268, 623-631.	3.6	9
40	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12185.	2.4	11
41	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12197.	2.4	4
42	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	5.9	42
43	Detection Gap of Right-Asymmetric Neuronal Degeneration by CERAD Test Battery in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 611595.	3.4	2
44	First symptom guides diagnosis and prognosis in neurodegenerative diseases—a retrospective study of autopsy proven cases. <i>European Journal of Neurology</i> , 2021, 28, 1801-1811.	3.3	11
45	Quantifying progression in primary progressive aphasia with structural neuroimaging. <i>Alzheimer's and Dementia</i> , 2021, 17, 1595-1609.	0.8	22
46	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 608-616.	1.9	10
47	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. <i>Brain</i> , 2021, 144, 2176-2185.	7.6	66
48	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , 2021, 11, 239-249.	1.7	18
49	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.1	52
50	Bundle-specific associations between white matter microstructure and A β and tau pathology in preclinical Alzheimer's disease. <i>ELife</i> , 2021, 10, .	6.0	26
51	Cortical [¹⁸ F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. <i>Movement Disorders</i> , 2021, 36, 2104-2115.	3.9	46
52	Binding characteristics of [¹⁸ F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2957-2972.	4.3	30
53	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3872-3885.	6.4	22
54	Dual-Phase β -Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 661284.	3.4	13

#	ARTICLE	IF	CITATIONS
55	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 484.	2.4	11
56	Characterizing the Clinical Features and Atrophy Patterns of <i>MAPT</i> -Related Frontotemporal Dementia With Disease Progression Modeling. <i>Neurology</i> , 2021, 97, e941-e952.	1.1	29
57	Low-degree trisomy 21 mosaicism promotes early-onset Alzheimer disease. <i>Neurobiology of Aging</i> , 2021, 103, 147.e1-147.e5.	3.1	4
58	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	6.2	12
59	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [18F]PI-2620. <i>Frontiers in Neurology</i> , 2021, 12, 684523.	2.4	11
60	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	10.2	26
61	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , The, 2021, 20, 605-614.	10.2	29
62	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 5346.	12.8	43
63	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	3.1	3
64	Modeling autosomal dominant Alzheimer's disease with machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, 1005-1016.	0.8	12
65	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28
66	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	2.7	8
67	Cognitive reserve hypothesis in frontotemporal dementia: A FDG-PET study. <i>NeuroImage: Clinical</i> , 2021, 29, 102535.	2.7	13
68	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.1	16
69	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	3.9	13
70	Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12184.	2.4	10
71	Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. <i>Science Translational Medicine</i> , 2021, 13, eabe5640.	12.4	108
72	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 4582.	2.4	9

#	ARTICLE	IF	CITATIONS
73	COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. Journal of Clinical Medicine, 2021, 10, 5125.	2.4	24
74	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
75	Associations between sex, body mass index, and the individual microglial response in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
76	A data-driven disease progression model of fluid biomarkers in genetic FTD. Alzheimer's and Dementia, 2021, 17, .	0.8	0
77	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	1
78	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4-Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	3.9	37
79	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. Information Fusion, 2020, 58, 153-167.	19.1	17
80	Drip and ship for mechanical thrombectomy within the Neurovascular Network of Southwest Bavaria. Neurology, 2020, 94, e453-e463.	1.1	17
81	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
82	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. Movement Disorders, 2020, 35, 595-605.	3.9	42
83	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. Brain Communications, 2020, 2, fcaa102.	3.3	11
84	Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning. Journal of Neuroinflammation, 2020, 17, 208.	7.2	19
85	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
86	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	1.9	25
87	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1325-1328.	1.9	12
88	Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12038.	2.4	9
89	Assessment of ¹⁸ F-Pi-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology, 2020, 77, 1408.	9.0	145
90	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.8	35

#	ARTICLE	IF	CITATIONS
91	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	3.3	20
92	Seizures in Alzheimer's disease are highly recurrent and associated with a poor disease course. Journal of Neurology, 2020, 267, 2941-2948.	3.6	38
93	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	4.4	31
94	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
95	Longitudinal correlation between neurofilament light chain and UMSARS in Multiple System Atrophy. Clinical Neurology and Neurosurgery, 2020, 195, 105924.	1.4	3
96	Binding of Metal-Ion-Induced Tau Oligomers to Lipid Surfaces Is Enhanced by GSK-3 β -Mediated Phosphorylation. ACS Chemical Neuroscience, 2020, 11, 880-887.	3.5	8
97	Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson's disease: A multi-modal atlas study with transcranial ultrasound and MRI. Neurolmage: Clinical, 2020, 26, 102185.	2.7	18
98	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	1.9	106
99	The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 2020, 35, 650-661.	3.9	31
100	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2020, 16, 219-228.	0.8	13
101	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	1.9	55
102	Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. PLoS ONE, 2020, 15, e0231495.	2.5	11
103	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2911-2922.	6.4	36
104	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19
105	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.8	47
106	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
107	Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. Neurolmage: Clinical, 2019, 24, 101949.	2.7	14
108	Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau. Alzheimer's Research and Therapy, 2019, 11, 67.	6.2	28

#	ARTICLE	IF	CITATIONS
109	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735.	10.2	79
110	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	10.2	128
111	PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 249.	3.4	30
112	Identification of a rare presenilin 1 single amino acid deletion mutation (F175del) with unusual amyloid- β processing effects. <i>Neurobiology of Aging</i> , 2019, 84, 241.e5-241.e11.	3.1	9
113	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , 2019, 25, 277-283.	30.7	610
114	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. <i>Translational Psychiatry</i> , 2019, 9, 54.	4.8	28
115	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	4.2	33
116	Programming parameters of subthalamic deep brain stimulators in Parkinson's disease from a controlled trial. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 217-223.	2.2	6
117	Four-repeat tauopathies. <i>Progress in Neurobiology</i> , 2019, 180, 101644.	5.7	141
118	Opposite microglial activation stages upon loss of <scp>PGRN</scp> or <scp>TREM</scp> 2 result in reduced cerebral glucose metabolism. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	87
119	Education modulates brain maintenance in presymptomatic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1124-1130.	1.9	23
120	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
121	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440.	7.6	36
122	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	3.9	93
123	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 655-665.	0.8	72
124	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. <i>Cortex</i> , 2019, 117, 33-40.	2.4	17
125	Multiple system atrophy. <i>International Review of Neurobiology</i> , 2019, 149, 137-192.	2.0	74
126	Parkinsonism in genetic and sporadic Alzheimer's disease. <i>International Review of Neurobiology</i> , 2019, 149, 237-247.	2.0	2

#	ARTICLE	IF	CITATIONS
127	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27
128	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. <i>JAMA Network Open</i> , 2019, 2, e1917126.	5.9	23
129	Increased cerebral microbleeds and cortical superficial siderosis in pediatric patients with Down syndrome. <i>European Journal of Paediatric Neurology</i> , 2019, 23, 158-164.	1.6	8
130	A baseline study for detection of Parkinson's disease with 3D-transcranial sonography and uni-lateral reconstruction. <i>Journal of the Neurological Sciences</i> , 2019, 397, 16-21.	0.6	2
131	Different Effects of Î±-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1649-1659.	3.5	44
132	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 18-23.	3.1	27
133	Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-Î² pathology. <i>Molecular Neurodegeneration</i> , 2019, 14, 1.	10.8	253
134	The applause sign in frontotemporal lobar degeneration and related conditions. <i>Journal of Neurology</i> , 2019, 266, 330-338.	3.6	15
135	ICP-161: 18F-P12620 TAU-PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTI-CENTER EVALUATION. <i>Alzheimer's and Dementia</i> , 2019, 15, P128.	0.8	3
136	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , 2018, 141, 1186-1200.	7.6	83
137	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	7.6	79
138	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , The, 2018, 17, 241-250.	10.2	383
139	Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. <i>Lancet Neurology</i> , The, 2018, 17, 223-231.	10.2	105
140	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 41.	6.2	8
141	Three cases of isolated resting tremor of the lower limbs. <i>Basal Ganglia</i> , 2018, 11, 1-3.	0.3	1
142	Symptomatic therapy of multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2018, 211, 26-30.	2.8	18
143	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 239-247.	1.9	89
144	P1497: CLINICAL CORRELATES OF LEWY BODY PATHOLOGY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P520.	0.8	0

#	ARTICLE	IF	CITATIONS
145	P4â€094: OCCIPITAL TO GLOBAL PIB UPTAKE IS ASSOCIATED WITH THE PRESENCE OF MICROHEMORRHAGES AND MUTATIONS ASSOCIATED WITH CEREBRAL AMYLOID ANGIOPATHY IN THE DOMINANTLY INHERITED ALZHEIMER'S NETWORK. Alzheimer's and Dementia, 2018, 14, P1472.	0.8	1
146	ICâ€Pâ€090: CROSSâ€VALIDATED BIOMARKERâ€BASED PREDICTION OF 4â€YEAR RATE OF COGNITIVE DECLINE IN NONâ€DEMENTED SUBJECTS AT RISK OF AD. Alzheimer's and Dementia, 2018, 14, P75.	0.8	1
147	ICâ€Pâ€067: THE BDNFVAL66MET SNP IS RELATED TO HIPPOCAMPAL CONNECTIVITY AND COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P60.	0.8	0
148	P3â€426: CROSSâ€VALIDATED BIOMARKERâ€BASED PREDICTION OF 4â€YEAR RATE OF COGNITIVE DECLINE IN NONâ€DEMENTED SUBJECTS AT RISK OF AD. Alzheimer's and Dementia, 2018, 14, P1273.	0.8	0
149	<sc>CSF</sc> progranulin increases in the course of Alzheimer's disease and is associated with <sc>STREM</sc> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	6.9	64
150	O4â€04â€05: FIBERâ€TRACTâ€SPECIFIC DECLINE IN WHITEâ€MATTER INTEGRITY DURING THE ADULT LIFESPAN AND PRECLINICAL ALZHEIMER'S DISEASE: RESULTS FROM THE DALLAS LIFESPAN BRAIN STUDY AND DIAN. Alzheimer's and Dementia, 2018, 14, P1410.	0.8	0
151	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 703-713.	3.7	63
152	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€™s disease. Brain, 2018, 141, 3065-3080.	7.6	116
153	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.8	51
154	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.1	193
155	IgLON5: A case with predominant cerebellar tau deposits and leptomeningeal inflammation. Neurology, 2018, 91, 180-182.	1.1	23
156	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients â€“ An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	3.4	40
157	Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?. Frontiers in Neurology, 2018, 9, 483.	2.4	21
158	Effect of <i>BDNF</i>Val66Met on disease markers in dominantly inherited Alzheimer's disease. Annals of Neurology, 2018, 84, 424-435.	5.3	25
159	Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. Current Opinion in Neurology, 2018, 31, 448-454.	3.6	19
160	Multiple System Atrophy. , 2017, , 183-192.		2
161	Polyâ€<sc>GP</sc> in cerebrospinal fluid links <i>C9orf72</i>â€associated dipeptide repeat expression to the asymptomatic phase of <sc>ALS</sc>/<sc>FTD</sc>. EMBO Molecular Medicine, 2017, 9, 859-868.	6.9	90
162	Hough-CNN: Deep learning for segmentation of deep brain regions in MRI and ultrasound. Computer Vision and Image Understanding, 2017, 164, 92-102.	4.7	282

#	ARTICLE	IF	CITATIONS
163	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
164	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
165	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Scientific Reports, 2017, 7, 1225.	3.3	42
166	MR imaging differentiation of Fe ²⁺ and Fe ³⁺ based on relaxation and magnetic susceptibility properties. Neuroradiology, 2017, 59, 403-409.	2.2	36
167	Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2239-2248.	6.4	15
168	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. Movement Disorders, 2017, 32, 1356-1364.	3.9	11
169	[P4 ¹⁸⁹]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1337.	0.8	2
170	Cerebral Glucose Metabolism and Dopaminergic Function in Patients with Corticobasal Syndrome. Journal of Neuroimaging, 2017, 27, 255-261.	2.0	23
171	Multivariate Analysis of 18F-DMFP PET Data to Assist the Diagnosis of Parkinsonism. Frontiers in Neuroinformatics, 2017, 11, 23.	2.5	32
172	Perfusion-Phase [18F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration. Journal of Alzheimer's Disease Reports, 2017, 1, 109-113.	2.2	8
173	[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. Frontiers in Aging Neuroscience, 2017, 9, 440.	3.4	58
174	Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice. PLoS ONE, 2017, 12, e0188989.	2.5	11
175	The Differential Diagnosis and Treatment of Atypical Parkinsonism. Deutsches Ärztblatt International, 2016, 113, 61-9.	0.9	135
176	Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. Frontiers in Neuroscience, 2016, 10, 99.	2.8	23
177	Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Science Translational Medicine, 2016, 8, 369ra178.	12.4	211
178	Applied multimodal diagnostics in a case of presenile dementia. BMC Neurology, 2016, 16, 131.	1.8	3
179	<i>BDNF</i> Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain, 2016, 139, 2766-2777.	7.6	70
180	Current Treatment of Multiple System Atrophy. Current Treatment Options in Neurology, 2016, 18, 51.	1.8	9

#	ARTICLE	IF	CITATIONS
181	Intracellular formation of α -synuclein oligomers and the effect of heat shock protein 70 characterized by confocal single particle spectroscopy. Biochemical and Biophysical Research Communications, 2016, 477, 76-82.	2.1	4
182	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission, 2016, 123, 439-445.	2.8	32
183	Psychosis in Parkinson's disease: identification, prevention and treatment. Journal of Neural Transmission, 2016, 123, 45-50.	2.8	39
184	Hypometabolism in Brain of Cognitively Normal Patients with Depressive Symptoms is Accompanied by Atrophy-Related Partial Volume Effects. Current Alzheimer Research, 2016, 13, 475-486.	1.4	12
185	slan-defined subsets of CD16-positive monocytes: impact of granulomatous inflammation and M-CSF receptor mutation. Blood, 2015, 126, 2601-2610.	1.4	116
186	Analysis of 18F-DMFP PET data using multikernel classification in order to assist the diagnosis of Parkinsonism. , 2015, , .		8
187	Distinguishing Parkinson's disease from atypical parkinsonian syndromes using PET data and a computer system based on support vector machines and Bayesian networks. Frontiers in Computational Neuroscience, 2015, 9, 137.	2.1	23
188	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathologica, 2015, 130, 537-555.	7.7	157
189	The association of aphasia and right-sided motor impairment in corticobasal syndrome. Journal of Neurology, 2015, 262, 2241-2246.	3.6	9
190	Extracellular vesicle sorting of α -Synuclein is regulated by sumoylation. Acta Neuropathologica, 2015, 129, 695-713.	7.7	136
191	Postinfectious Opsoclonus-Myoclonus Syndrome in a 41-Year-Old Patient-Visualizing Hyperactivation in Deep Cerebellar Nuclei by Cerebral [¹⁸ F]-FDG-PET. Journal of Neuroimaging, 2015, 25, 683-685.	2.0	9
192	Oligoclonal bands in hereditary diffuse leukoencephalopathy with spheroids. European Journal of Neurology, 2015, 22, e48-e48.	3.3	0
193	Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathologica, 2015, 130, 619-631.	7.7	58
194	Modelling Ser129 Phosphorylation Inhibits Membrane Binding of Pore-Forming Alpha-Synuclein Oligomers. PLoS ONE, 2014, 9, e98906.	2.5	24
195	Onset latency of segmental dystonia after deep brain stimulation cessation: A randomized, double-blind crossover trial. Movement Disorders, 2014, 29, 944-949.	3.9	13
196	Diffuse leukoencephalopathy with spheroids: Biopsy findings and a novel mutation. Clinical Neurology and Neurosurgery, 2014, 122, 113-115.	1.4	10
197	The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathologica, 2014, 127, 779-780.	7.7	103
198	Neurostimulation for Parkinson's Disease with Early Motor Complications. New England Journal of Medicine, 2013, 368, 610-622.	27.0	1,138

#	ARTICLE	IF	CITATIONS
199	Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. <i>Acta Neuropathologica</i> , 2013, 125, 795-813.	7.7	327
200	A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. <i>Advances in Urology</i> , 2012, 2012, 1-10.	1.3	101
201	Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. <i>Experimental Neurology</i> , 2012, 237, 470-476.	4.1	41
202	Pontine and extrapontine myelinolysis associated with hypernatraemia. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 1290-1291.	1.4	13
203	Two Different Binding Modes of α -Synuclein to Lipid Vesicles Depending on its Aggregation State. <i>Biophysical Journal</i> , 2012, 102, 1646-1655.	0.5	39
204	G.P.123 Identification of molecular effects of FHL1 mutations on protein assembly in reducing body myopathy. <i>Neuromuscular Disorders</i> , 2012, 22, 903.	0.6	0
205	Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with α -synuclein at the single molecule level. <i>Molecular Neurodegeneration</i> , 2012, 7, 35.	10.8	60
206	Single-Channel Electrophysiology Reveals a Distinct and Uniform Pore Complex Formed by α -Synuclein Oligomers in Lipid Membranes. <i>PLoS ONE</i> , 2012, 7, e42545.	2.5	75
207	Generation of Ferric Iron Links Oxidative Stress to α -Synuclein Oligomer Formation. <i>Journal of Parkinson's Disease</i> , 2011, 1, 205-216.	2.8	58
208	Alpha frequency modulation in the human basal ganglia is dependent on motor task. <i>European Journal of Neuroscience</i> , 2011, 33, 960-967.	2.6	27
209	Inhibition and disaggregation of α -synuclein oligomers by natural polyphenolic compounds. <i>FEBS Letters</i> , 2011, 585, 1113-1120.	2.8	240
210	Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 2097-2099.	3.6	4
211	Divergent Molecular Effects of Desmin Mutations on Protein Assembly in Myofibrillar Myopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 415-424.	1.7	13
212	Elevated Levels of Methylmalonate and Homocysteine in Parkinson's Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 553-559.	1.5	40
213	The Value of the Dopamine D _{2/3} Receptor Ligand ¹⁸ F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes. <i>Journal of Nuclear Medicine</i> , 2010, 51, 581-587.	5.0	51
214	Converse modulation of toxic α -synuclein oligomers in living cells by N ² -benzylidene-benzohydrazide derivatives and ferric iron. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 461-466.	2.1	52
215	Objective measurement of muscle rigidity in parkinsonian patients treated with subthalamic stimulation. <i>Movement Disorders</i> , 2009, 24, 57-63.	3.9	58
216	Essential tremor leading to toxic liver damage successfully treated with deep brain stimulation. <i>Acta Neurochirurgica</i> , 2009, 151, 1305-1307.	1.7	4

#	ARTICLE	IF	CITATIONS
217	Increased β -synuclein aggregation following limited cleavage by certain matrix metalloproteinases. <i>Experimental Neurology</i> , 2009, 215, 201-208.	4.1	80
218	Single Particle Characterization of Iron-induced Pore-forming β -Synuclein Oligomers. <i>Journal of Biological Chemistry</i> , 2008, 283, 10992-11003.	3.4	204
219	First symptom in sporadic Creutzfeldt-Jakob disease. <i>Neurology</i> , 2006, 66, 286-287.	1.1	140
220	Single particle analysis of manganese-induced prion protein aggregates. <i>Biochemical and Biophysical Research Communications</i> , 2005, 329, 1200-1207.	2.1	45
221	Effect of metal ions on de novo aggregation of full-length prion protein. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 1240-1246.	2.1	92
222	CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
223	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.8	2